Browsing by Author "Yekeduz, Emre"
Now showing items 1-7 of 7
-
The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study
Guven, Deniz Can; Yekeduz, Emre; Erul, Enes; Coskun Yazgan, Sati; Sahin, Taha Koray; Karatas, Gokturk; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of ... -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan; Yildirim, Hasan Cagri; Tunc, Sezai; Ozyurt, Neslihan; Ozdemir, Feyyaz; Sendur, Mehmet Ali Nahit; Kilickap, Saadettin (LIPPINCOTT WILLIAMS & WILKINS, 2022)Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan (SPRINGER, 2022)Aim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib. Methods We included ... -
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Ozguroglu, Mustafa; Kucukarda, Ahmet; Sever, Ozlem Nuray; Kilickap, Saadettin; Oksuzoglu, Berna; Demirci, Umut; Arikan, Nuriye (Elsevier, 2022)Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the ... -
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Kilickap, Saadettin (Future Medicine, 2021)Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes ... -
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish oncology group kidney cancer consortium (TKCC) study
Tural, Deniz; Yekeduz, Emre; Erturk, Ismail; Karakaya, Serdar; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay; Sever, Ozlem Nuray; Senturk Oztas, Nihan; Kucukarda, Ahmet; Can, Orcun; Oksuzoglu, Berna; Sendur, Mehmet Ali; Karadurmus, Nuri; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Background Pan-immune-infammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients ... -
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
Yucel, Kadriye Bir; Yekeduz, Emre; Karakaya, Serdar; Tural, Deniz; Erturk, Ismail; Erol, Cihan; Ercelep, Ozlem; Oztas Senturk, Nihan; Arslan, Cagatay; Ucar, Gokhan; Kucukarda, Ahmet; Sever, Ozlem Nuray; Kilickap, Saadettin; Can, Orcun; Yazgan, Sati Coskun; Oksuzoglu, Berna; Karadurmus, Nuri; Sendur, Mehmet Ali; Urun, Yuksel (Nature Research, 2022)This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated ...
